Clinical Trial

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Study acronym: Galileo
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Protocol Amendment History 3 changes
notable Enrollment increased: 44 -> 52 participants 2026-06-09
notable Primary completion pushed: 2026-12-22 -> 2027-02-02 2026-06-09
minor Completion pushed: 2026-12-22 -> 2027-02-02 2026-06-09
Trial Details
NCT Number NCT06185764
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Myotonic Dystrophy Type 1 (DM1)
Enrollment 52 participants
Start Date 2024-02-20
Primary Completion 2027-02-02 (estimated)
Study Completion 2027-02-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-08